<<  Back

Jan 18, 2012

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline

Celldex Therapeutics to Host Research and Development Day Highlighting Oncology PipelineNEEDHAM, Mass.--(BUSINESS WIRE)--Jan. 18, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that it will host a research and development day for the investment community on Monday, January 23, 2012 at 8:30 am Eastern Time. The event will provide updates on the Company’s robust pipeline in oncology and cancer immunotherapy, featuring presentations from leading researchers and investigators as well as Celldex management. For information on attending the event, please contact Sarah Cavanaugh at scavanaugh@macbiocom.com.

Guest speakers:

  • John Sampson, M.D., Ph.D., Dr. Robert H. Wilkins and Gloria Wilkins Professor of Neurosurgery & Associate Deputy Director, The Preston Robert Tisch Brain Tumor Center Duke University Medical Center, Durham, NC
  • Linda T. Vahdat, M.D., Professor of Medicine, Weill Cornell Medical College & Attending Physician, New York-Presbyterian Hospital, New York, NY
  • Jeffrey S. Weber, M.D., Ph.D., Director, Donald A. Adam Comprehensive Melanoma Research Center, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

A live webcast of the event, including slides, will be available on the Presentations page of the Investors section of Celldex’s website at http://http://www.celldextherapeutics.com and will be archived for a limited time following the event. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.

Source: Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.
Anthony S. Marucci, 781-433-0771
President and CEO
or
Avery W. Catlin, 781-433-0771
Chief Financial Officer
IR@celldextherapeutics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
scavanaugh@macbiocom.com
or
Chris Erdman, 781-235-3060
cerdman@macbiocom.com

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline